InsiderTrades.com logo

COEP Insider Trading

Insider Ownership Percentage: 24.25%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Coeptis Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Coeptis Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Coeptis Therapeutics Share Price & Price History

Current Price: $15.41
Price Change: ▼ Price Decrease of -0.295 (-1.88%)
As of 12/8/2025 02:07 PM ET

This chart shows the closing price history over time for COEP up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Coeptis Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/12/2024Tara DesilvaDirectorBuy113$11.60$1,310.801,613View SEC Filing Icon  
1/10/2024Brian CogleyCFOBuy250$13.40$3,350.001,500View SEC Filing Icon  
1/8/2024David MehalickCEOBuy1,000$13.20$13,200.00139,130View SEC Filing Icon  
1/5/2024Daniel Alexander YeraceVPBuy542$13.80$7,479.6053,572View SEC Filing Icon  
1/5/2024David MehalickCEOBuy252$13.80$3,477.60138,130View SEC Filing Icon  
1/5/2024Gene SalkindDirectorBuy580$13.80$8,004.0014,202View SEC Filing Icon  
8/29/2023Gene SalkindDirectorBuy200$20.20$4,040.00202View SEC Filing Icon  
8/25/2023Gene SalkindDirectorBuy1,431$18.20$26,044.201,431View SEC Filing Icon  
8/23/2023Chris CaliseDirectorBuy579$18.80$10,885.2073,244View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Coeptis Therapeutics (NASDAQ:COEP)

13.88% of Coeptis Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at COEP by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Coeptis Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/18/2025Yorkville Advisors Global LP8,000$0.14M0.0%N/A0.166%Search for SEC Filing on Google Icon
2/13/2024Armistice Capital LLC3,520,000$2.76M0.0%+59.1%10.320%Search for SEC Filing on Google Icon
11/15/2023Armistice Capital LLC2,212,000$2.57M0.0%-5.1%8.799%Search for SEC Filing on Google Icon
8/15/2023Ionic Capital Management LLC45,000$70K0.0%N/A0.209%Search for SEC Filing on Google Icon
7/21/2023Creative Planning645,103$1M0.0%N/A2.995%Search for SEC Filing on Google Icon
5/12/2023Antara Capital LP45,000$64K0.0%N/A0.220%Search for SEC Filing on Google Icon
2/14/2023Susquehanna International Group LLP16,341$25K0.0%N/A0.319%Search for SEC Filing on Google Icon
2/10/2023Creative Planning645,103$0.99M0.0%N/A12.600%Search for SEC Filing on Google Icon
2/10/2023HRT Financial LP172,635$0.27M0.0%N/A3.372%Search for SEC Filing on Google Icon
2/8/2023Cambridge Investment Research Advisors Inc.31,670$48K0.0%N/A0.619%Search for SEC Filing on Google Icon
2/6/2023West Chester Capital Advisors Inc.2,863,382$4.39M8.7%N/A55.925%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Coeptis Therapeutics logo
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Read More on Coeptis Therapeutics

Today's Range

Now: $15.41
Low: $15.30
High: $16.12

50 Day Range

MA: $15.87
Low: $13.71
High: $18.80

52 Week Range

Now: $15.41
Low: $2.31
High: $21.41

Volume

24,359 shs

Average Volume

73,476 shs

Market Capitalization

$82.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Coeptis Therapeutics?

Coeptis Therapeutics' top insider investors include:
  1. David Mehalick (CEO)
  2. Daniel Alexander Yerace (VP)
  3. Gene Salkind (Director)
  4. Tara Desilva (Director)
  5. Brian Cogley (CFO)
Learn More about top insider investors at Coeptis Therapeutics.

Who are the major institutional investors of Coeptis Therapeutics?

Coeptis Therapeutics' top institutional shareholders include:
  1. Yorkville Advisors Global LP — 0.17%
Learn More about top institutional investors of Coeptis Therapeutics stock.

Which major investors are buying Coeptis Therapeutics stock?

In the last quarter, COEP stock was purchased by institutional investors including:
  1. Yorkville Advisors Global LP
During the previous year, these company insiders have bought Coeptis Therapeutics stock:
  1. David Mehalick (CEO)
  2. Daniel Alexander Yerace (VP)
  3. Gene Salkind (Director)
  4. Tara Desilva (Director)
  5. Brian Cogley (CFO)
Learn More investors buying Coeptis Therapeutics stock.